Fig. 4From: Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancerAPR-246 sensitized primary ovarian cancer cells with TP53 mutation to cisplatin. The FMCA assay was used to assess cell viability after 72 h incubation with drugs. This ascites sample was taken from a clinically platinum-resistant patient. The results shown are mean ± SEM (n = 2)Back to article page